Mega Contracts Monitor ($100M+) — June 12, 2026

The firm-fixed-price delivery order from HHS/ASPR, with $83.5M already funded, provides strong revenue visibility through 2027 for this small business. Full-and-open competition suggests Partner Therapeutics won on merit, reinforcing its competitive position in government health security procurement.

The cost-plus-fixed-fee structure limits margin upside but ensures margin protection, while the 7.5-year duration supports predictable revenue streams. Full-and-open competition signals strong competitive standing against other large primes.

The firm-fixed-price pricing transfers cost overrun risk to CADDELL, and the 4.6-year construction timeline introduces potential for delays or cost escalations. Any cost overruns would directly impact margins.

The firm-fixed-price BPA call for IT application development support carries execution risk, though labor-based services partially mitigate this. The negligible negative outlay (-$5,924) is not material but warrants monitoring for any systemic accounting issues.

CADDELL's $322M firm-fixed-price consulate construction contract for the Department of State introduces cost overrun risk, with a 4.6-year timeline that could face delays or scope changes.

Peraton's $121.6M fixed-price IT contract for GSA FAS carries cost overrun risk, though labor-based services are typically lower risk. The negative outlay (-$5,924) is negligible but could indicate minor accounting adjustments.

ACUMEN's $167.3M CMS contract has $149.7M already outlayed (89.5%), but the contract ends September 2026 with no exercised options beyond the base period, creating re-compete risk.

GSA awarded three of six contracts (MANTECH $452M, SAIC $291M, Peraton $122M), representing 58% of total obligation. This concentration exposes investors to GSA budget and policy shifts.

MANTECH's $452M GSA R&D contract through 2027 signals sustained demand for applied research services across civilian agencies, offering multi-year revenue visibility for the company.

Partner Therapeutics' $133.5M HHS contract for Leukine highlights growing government investment in medical preparedness, which could expand to DOD medical logistics contracts.

CADDELL's $322M State Department consulate contract indicates robust diplomatic facilities spending, which could lead to follow-on awards for similar projects in other countries.

Four of six contracts (MANTECH $452M, SAIC $291M, ACUMEN $167M, Peraton $122M) are for IT, R&D, or consulting services to civilian agencies, totaling $1.03B or 69% of aggregate value. This underscores durable demand for technology modernization and management support outside defense.

Partner Therapeutics' $133.5M HHS contract for Leukine, a pharmaceutical preparation, highlights government focus on medical countermeasures and stockpiling, a theme that may cross over to DOD.

Two contracts (CADDELL $322M construction, Peraton $122M IT) are firm-fixed-price, shifting cost overrun risk to contractors. While labor-based IT services are lower risk, construction projects face material and labor cost volatility.

{"entity"=>"MANTECH International Corporation", "reason"=>"Largest contract in the digest ($452M) with multi-year revenue visibility through 2027; key GSA FEDSIM relationship.", "trigger"=>"GSA FEDSIM subsequent R&D awards or option exercises"}

{"entity"=>"Partner Therapeutics, Inc.", "reason"=>"Bullish signal on $133.5M HHS contract; private company but could be acquisition target for larger pharma.", "trigger"=>"HHS/ASPR budget increases or NDAA medical preparedness provisions"}

{"entity"=>"CADDELL CONSTRUCTION CO. (DE), LLC", "reason"=>"High execution risk on $322M fixed-price consulate contract; any cost overrun disclosures would be material.", "trigger"=>"Quarterly earnings reports or contract modification announcements"}

{"entity"=>"ACUMEN LLC", "reason"=>"CMS contract ending September 2026 with 89.5% already outlayed; re-compete risk is high.", "trigger"=>"CMS budget allocation for DATALINK program or re-compete RFP"}